Key facts
- Jiangsu Vcare’s last known valuation is $162.4M (Feb 2021).
- It has raised $225.4M; the latest was Later Stage VC ($27.3M) in Jan 2025.
- Notable investors include Zijin Hi-Tech Venture Capital, CMG SDIC Fund, Nanjing Innovation Capital Group, Hubei Yangtze River Industrial Investment Group, China Life Private Equity — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Jiangsu Vcare
- ·The full record, as it builds
Funding rounds
No funding rounds for Jiangsu Vcare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jiangsu Vcare
Developer of innovative drugs designed to treat cardiovascular and cerebrovascular, tumors, endocrine, and other areas of chronic diseases. The company's drugs focus on chemical molecular structure optimization and differentiated solutions to clinical needs in the form of generic and innovative drugs and featured pharmaceutical intermediates, providing research and development services for the whole industry chain of chemical drugs.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2010
- Employees
- 900
- Website
- vcarepharmatech.com/
- Ownership
- Privately Held (backing)
Jiangsu Vcare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jiangsu Vcare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jiangsu Vcare in its N-PORT filings yet. We sweep new filings monthly.